Clinical Trial Update: Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety, pharmacodynamics, and pharmacokinetics of multiple peginesatide doses for anemia in chronic kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• OMontys (peginesatide)

Snippet

Sponsor: Affymax | Conditions: Anemia, Chronic Kidney Disease | Phase 2 | Status: COMPLETED